Learn everything you need to know about Fosphenytoin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...

Review the side-effects of Fosphenytoin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Credit: Shutterstock. The product is a ready-to-dilute, room temperature stable formulation of fosphenytoin for IV injection, which allows for point-of-care storage. The Food and Drug Administration ...

PAOLI, Pa.--(BUSINESS WIRE)--Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT (fosphenytoin sodium for injection) for the ...

Credit: Shutterstock. The product is being reviewed as a treatment for generalized tonic-clonic status epilepticus, for the prevention and treatment of seizures occurring during neurosurgery, as a ...

SAN DIEGO — Intravenous (IV) administration of the anticonvulsant fosphenytoin is effective as a fast-acting treatment for acute trigeminal neuralgia (TN) exacerbation, new research suggested. TN is a ...

The choice of drugs for patients with status epilepticus that is refractory to treatment with benzodiazepines has not been thoroughly studied. In a randomized, blinded, adaptive trial, we compared the ...

Nobelpharma Co., Ltd. (Headquarters: Tokyo, President & CEO: Jin Shiomura, "Nobelpharma") and Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito ...

November 4, 2010 — A joint panel of experts has told the US Food and Drug Administration (FDA) in no uncertain terms that intravenous (IV) phenytoin, used to treat epileptic seizures, should remain on ...

This is an AP member exchange shared by the Lawrence Journal-World. LAWRENCE — There’s a high chance you know someone whose life has been saved, extended or improved by a drug invented by University ...

Captisol-enabled™ product is stable at room temperature for timely administration at the point of patient care “We are pleased to see Sedor’s progress with SESQUIENT and today’s FDA approval for ...